Sarilumab, a humanized monoclonal antibody, has gained significant attention in the biopharmaceutical market for its role in treating moderate to severe rheumatoid arthritis (RA). The sarilumab market has seen significant advancements, particularly in the expanding use of the drug for COVID-19 treatment, where it has shown effectiveness in reducing inflammation in severe cases. Ongoing clinical trials are investigating its potential in other autoimmune diseases such as systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis, and even in combination therapies with other RA treatments. Despite its promise, the sarilumab market faces challenges, including competition from other RA biologics, concerns over side effects, and the high cost of treatment, which may limit accessibility in low-resource regions. However, with increasing research and new indications, the sarilumab market is expected to grow as more treatment options emerge.
